The nation of Zimbabwe has turned down a major US health deal worth $367m (£272m) spanning five years because of Washington's request for sensitive biological samples.
This rejection came to light following a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman later stated that the United States was requesting genetic material for research and profit while refused to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further negotiations to find a deal agreeable to both sides so the nation's vital HIV programme can continue.
Wider Context
This development follows a similar case in Kenya, where a high court blocked a related health funding agreement following legal challenges were raised about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
According to reports, 16 nations in Africa have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our population should a future disease outbreak arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting systems previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future pandemics.
"This mechanism is intended to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued discussions with our US partners on how subsequent co-operation might be designed in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body said it acknowledged the government's concerns, but urged that negotiations should continue since much of the nation's Aids initiatives depended on international support.
"In cases where specific concerns exist, including those involving information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it added.
The situation underscores the complex debate between receiving crucial foreign assistance and protecting local interests in an ever more data-driven world.